Cutera, Inc. (NASDAQ:CUTR) has received a consensus rating of “Buy” from the seven research firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $39.50.

Several research analysts have commented on CUTR shares. BidaskClub lowered Cutera from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Roth Capital lifted their price target on Cutera from $41.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday, September 12th. Zacks Investment Research lowered Cutera from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Maxim Group lowered Cutera from a “buy” rating to a “hold” rating in a research report on Thursday, September 14th. Finally, Gabelli reiterated a “buy” rating on shares of Cutera in a research note on Wednesday, August 9th.

In related news, CFO Ronald J. Santilli sold 12,000 shares of Cutera stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $34.00, for a total value of $408,000.00. Following the sale, the chief financial officer now directly owns 75,253 shares in the company, valued at $2,558,602. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director David B. Apfelberg sold 1,000 shares of Cutera stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $38.45, for a total value of $38,450.00. The disclosure for this sale can be found here. Insiders sold a total of 66,941 shares of company stock worth $2,403,457 over the last quarter. Company insiders own 3.30% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Morgan Stanley boosted its stake in shares of Cutera by 23.3% in the first quarter. Morgan Stanley now owns 67,345 shares of the medical device company’s stock valued at $1,395,000 after buying an additional 12,734 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of Cutera by 50.7% in the second quarter. Teachers Advisors LLC now owns 62,702 shares of the medical device company’s stock valued at $1,624,000 after buying an additional 21,088 shares in the last quarter. Kennedy Capital Management Inc. purchased a new stake in shares of Cutera in the second quarter valued at approximately $9,426,000. Scout Investments Inc. purchased a new stake in shares of Cutera in the second quarter valued at approximately $1,454,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Cutera by 0.8% in the second quarter. Renaissance Technologies LLC now owns 1,214,500 shares of the medical device company’s stock valued at $31,456,000 after buying an additional 9,100 shares in the last quarter. Hedge funds and other institutional investors own 89.72% of the company’s stock.

Cutera (NASDAQ CUTR) opened at $42.65 on Tuesday. The company has a market capitalization of $588.14, a P/E ratio of 54.42, a price-to-earnings-growth ratio of 1.84 and a beta of 0.49. Cutera has a 12-month low of $13.70 and a 12-month high of $44.40.

Cutera (NASDAQ:CUTR) last released its quarterly earnings results on Tuesday, November 7th. The medical device company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.08 by $0.34. The company had revenue of $38.17 million for the quarter, compared to analyst estimates of $34.82 million. Cutera had a return on equity of 18.73% and a net margin of 7.99%. The firm’s revenue was up 26.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.12 earnings per share. research analysts predict that Cutera will post 0.55 earnings per share for the current fiscal year.

Cutera declared that its Board of Directors has authorized a stock repurchase plan on Monday, August 7th that authorizes the company to repurchase $25.00 million in outstanding shares. This repurchase authorization authorizes the medical device company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its stock is undervalued.

ILLEGAL ACTIVITY NOTICE: “Cutera, Inc. (CUTR) Receives Average Recommendation of “Buy” from Analysts” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/11/13/cutera-inc-cutr-receives-average-recommendation-of-buy-from-analysts.html.

About Cutera

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Receive News & Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.